The Impact of Urinary Incontinence Related to Overactive Bladder on Long-Term Care Residents and Facilities in the U.S. Highlighted in New Survey

July 13, 2022 at 8:00am PST Survey of 71 Directors of Nursing (DONs) highlights a need for improved awareness, education, and management of urinary incontinence (UI) related to overactive bladder (OAB) in long-term care (LTC) settings, according to this peer-reviewed journal paper. Surveyed DONs reported an average of 62% of their residents had UI, with 81% of […]

Urovant Sciences® Named One of 2022 “Best Places to Work” in Orange County

July 7, 2022 at 8:07am PST  This is Urovant’s second year in a row to earn this recognition by Orange County Business Journal Urovant has also received a 2022 global Great Place to Work™ certification. The culmination of these two awards reflects the company’s people focused culture and underscores the opinion of employees, dedicated to improving […]

Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland

July 5, 2022 at 8:05am EST Pierre Fabre Médicament SAS (Pierre Fabre) to register and commercialize vibegron for the treatment of Overactive Bladder (OAB) in the European Economic Area, UK, and Switzerland. Urovant Sciences GmbH to receive compensation of up to USD $75 million in upfront payment, regulatory, and sales milestones as well as royalties […]

Urovant Sciences® Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting

May 15, 2022 at 10:00 AM EDT New analyses of data from the Phase 3 EMPOWUR Extension Study of GEMTESA® (vibegron) 75 mg provided additional insight into the long-term durability of the product. These data were featured in podium presentations PD 38-11 and PD 38-12: In a subgroup analysis of adults, 65 years old or above […]

Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting

May 13, 2022 at 11:30 PM CDT Interim 12-week analysis from an ongoing Phase 2a trial of an investigational novel gene therapy product (plasmid human cDNA encoding maxi-K channel) showed clinically relevant improvement in the common symptoms of overactive bladder (OAB) compared to placebo. (Plenary Presentation PLLBA-03) In this prespecified 12-week analysis of a Phase 2a […]

Urovant Sciences Announces Publication of EMPOWUR Trial Subgroup Analysis Showing Similar Efficacy for GEMTESA® (Vibegron) 75mg in Dry and Wet Overactive Bladder Populations

April 19, 2022 at 8:00 AM PDT Post-hoc analysis indicates significant reductions in urgency episodes and micturitions in patients treated with GEMTESA vs. placebo in both types of overactive bladder (OAB) Article appears in the peer-reviewed International Journal of Clinical Practice  Findings are consistent with overall data from the EMPOWUR study, showing favorable efficacy in patients with […]

Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 2022 American Urological Association Annual Meeting

April 13, 2022 at 9:00 AM PDT Interim 12-week analysis from a Phase 2a trial of the potential gene therapy, URO-902, in women with overactive bladder (OAB) and urge urinary incontinence (UUI) will be featured in a late breaker presentation by Kenneth M. Peters, M.D. during Friday morning’s plenary session. New analyses of data from […]

Urovant Sciences Announces Appointment of Sef Kurstjens as Executive Vice President and Chief Medical Officer

April 4, 2022 at 8:00 AM PDT IRVINE, Calif. & BASEL, Switzerland – April 4, 2022 – Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced Sef Kurstjens, M.D., PhD., has been appointed Executive Vice President and Chief Medical Officer (CMO). Concurrent with this appointment, Dr. Kurstjens will step down as a member of Urovant’s Board […]

Urovant Sciences Announces Publication of New Review of Efficacy and Safety Data for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients in the Journal Therapeutics and Clinical Risk Management

Review article in a peer-reviewed journal examines studies of GEMTESA published in the past 3 years Data support GEMTESA’s role as an effective treatment option for overactive bladder (OAB) based on studies including:  Two phase 3 trials (EMPOWUR, EMPOWUR extension) conducted with once daily vibegron 75 mg for the treatment of OAB Additional secondary and […]

Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902

March 7, 2022 at 11:30 AM EST Study showed clinically meaningful impact on common symptoms of overactive bladder (OAB) compared to placebo from baseline to week 12   IRVINE, Calif. & BASEL, Switzerland – March 7, 2022 – Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced positive topline results from its Phase 2a, double-blind, placebo-controlled exploratory […]